Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;31(3):1–6. [Article in Spanish] doi: 10.1016/S0212-6567(03)70671-4

Riesgo glucémico y contribución de la glucemia posprandial a la hemoglobina glucosilada (HbA1c)

FJ García Soidán 1,*
PMCID: PMC7684247

The content is available as a PDF (336.4 KB).

Bibliografía

  • 1.Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Metab. 1977;3:245–256. [PubMed] [Google Scholar]
  • 2.Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258–271. doi: 10.2337/diacare.18.2.258. [DOI] [PubMed] [Google Scholar]
  • 3.Klein R., Klein B.E.K., Moss S.E., David M.D., DeMets D.L. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. J Am Med Assoc. 1988;260:2864–2871. [PubMed] [Google Scholar]
  • 4.Liu Q.Z., Knowler W.C., Nelson R.G., Saad M.F., Charles M.A., Liebow I.M. Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians Cross sectional and prospective analyses. Diabetes. 1992;41:1141–1150. doi: 10.2337/diab.41.9.1141. [DOI] [PubMed] [Google Scholar]
  • 5.UKPDS., 33 Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853. [PubMed] [Google Scholar]
  • 6.Tan C., Chow W.S., Ai V., Metz C., Bucala R., Lam K.S. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care. 2002;25:1055–1059. doi: 10.2337/diacare.25.6.1055. [DOI] [PubMed] [Google Scholar]
  • 7.Rohlfing C., Wiedmeyer H.M., Little R.R., England J.D., Tennill A., Goldstein D.E. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275–278. doi: 10.2337/diacare.25.2.275. [DOI] [PubMed] [Google Scholar]
  • 8.Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest. 2000;30(Suppl 2):3–11. [PubMed] [Google Scholar]
  • 9.UKPDS., 34 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes UK Prospective Diabetes Study group. Lancet. 1998;352:854–865. [PubMed] [Google Scholar]
  • 10.Avignon A., Radauceanu A., Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822–1826. doi: 10.2337/diacare.20.12.1822. [DOI] [PubMed] [Google Scholar]
  • 11.Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117. doi: 10.1016/0168-8227(95)01064-k. [DOI] [PubMed] [Google Scholar]
  • 12.Nathan D., Singer D., Hurxthal K., Goodson J.D. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984;310:341–346. doi: 10.1056/NEJM198402093100602. [DOI] [PubMed] [Google Scholar]
  • 13.Svendson P., Lauritzen T., Soegaard U., Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. Diabetologia. 1982;23:403–405. doi: 10.1007/BF00260951. [DOI] [PubMed] [Google Scholar]
  • 14.Stratton I.M., Adler A.I., Neil A.W., Matthews D.R., Manley S.E., Cull C.A. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) BMJ. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.The, DCCT., Research Group The relationship of glycemic exposure to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968–983. [PubMed] [Google Scholar]
  • 16.The, DECODE., Study group Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ. 1998;317:371–375. doi: 10.1136/bmj.317.7155.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.The, DECODE., Study group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617–621. [PubMed] [Google Scholar]
  • 18.Harris M.I., Flegal K.M., Cowie C.C., Eberhardt M.S., Goldstein D.E., Little R.R. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults: The third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518–524. doi: 10.2337/diacare.21.4.518. [DOI] [PubMed] [Google Scholar]
  • 19.Erlinger T.P., Brancati F.L. Postchallenge hyperglycemia in a national sample of US adults with type 2 diabetes. Diabetes Care. 2001;24:1734–1738. doi: 10.2337/diacare.24.10.1734. [DOI] [PubMed] [Google Scholar]
  • 20.Ceriello A. The emerging role of post-prandial hyperglycemic spikes in the pathogenesis of diabetic complications. Diabet Med. 1998;15:188–193. doi: 10.1002/(SICI)1096-9136(199803)15:3<188::AID-DIA545>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  • 21.Verges B. The impact of regulation of postprandial glucose in practice. Diabetes Metab. 1999;25(Suppl 7):22–25. [PubMed] [Google Scholar]
  • 22.Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21–B29. [PubMed] [Google Scholar]
  • 23.Saydah S.H., Loria C.M., Eberhardt M.S., Brancati F.L. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24:447–453. doi: 10.2337/diacare.24.3.447. [DOI] [PubMed] [Google Scholar]
  • 24.The, DECODE., Study group Glucose tolerance and cardiovascular mortality Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–404. doi: 10.1001/archinte.161.3.397. [DOI] [PubMed] [Google Scholar]
  • 25.Bouma M., Dekker J.H., De Sonnaville J.J., Van der Does F.E., De Vries H., Kriegsman D.M. How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes? Diabetes Care. 1999;22:904–907. doi: 10.2337/diacare.22.6.904. [DOI] [PubMed] [Google Scholar]
  • 26.Soonthornpun S., Rattarasam C., Leelawattana R., Setasuban W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract. 1999;46:23–27. doi: 10.1016/s0168-8227(99)00061-3. [DOI] [PubMed] [Google Scholar]
  • 27.American College of Endocrinology/American Association of Clinical Endocrinologists The AACE medical guidelines for the management of diabetes mellitus. Endocrine Pract. 2002;8(Suppl 1):5–11. [Google Scholar]
  • 28.American Diabetes Association Clinical Practice Recommendations 2002. Diabetes Care. 2002;25(Suppl 1):1–139. doi: 10.2337/diacare.25.2007.s1. [DOI] [PubMed] [Google Scholar]
  • 29.Caputo S., Pitocco D., Ruotolo V., Ghirlanda G. What is the real contribution of fasting plasma glucose and postprandial glucose in predicting HbA1c and overall blood glucose control? Diabetes Care. 2001;24:2011. doi: 10.2337/diacare.24.11.2011. [DOI] [PubMed] [Google Scholar]
  • 30.American Diabetes Association Postprandial blood glucose. Diabetes Care. 2002;24:775–779. doi: 10.2337/diacare.24.4.775. [DOI] [PubMed] [Google Scholar]
  • 31.Parkin C.G., Brooks N. Is postprandial glucose control important? Is it practical in primary care settings? Clinical Diabetes. 2002;20:71–76. [Google Scholar]
  • 32.Bonora E., Calcaterra F., Lombardi S., Bonfante N., Formentini G., Bonadonna R.C. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001;24:2023–2029. doi: 10.2337/diacare.24.12.2023. [DOI] [PubMed] [Google Scholar]
  • 33.Bastyr E., Stuart C.A., Brodows R.G., Schwartz S., Graf C.J., Zagar Z. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c IOEZ Study group. Diabetes Care. 2000;23:1236–1241. doi: 10.2337/diacare.23.9.1236. [DOI] [PubMed] [Google Scholar]
  • 34.Ciofetta M., Lalli S., Del Sindaco P., Torlone E., Pampanelli S., Mauro L. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care. 1999;22:795–800. doi: 10.2337/diacare.22.5.795. [DOI] [PubMed] [Google Scholar]
  • 35.Reaven G., Hollenbeck C., Jeng C.Y., Wu M.S., Chen Y.D. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes. 1988;37:1020–1024. doi: 10.2337/diab.37.8.1020. [DOI] [PubMed] [Google Scholar]
  • 36.Gerstein H., Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet. 1996;347:949–950. doi: 10.1016/s0140-6736(96)91420-8. [DOI] [PubMed] [Google Scholar]
  • 37.Horton E.S., Clinkingbeard C., Gatlin M., Foley J., Mallows S., Shen S. Nateglinide alone and in combination with metformnin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660–1665. doi: 10.2337/diacare.23.11.1660. [DOI] [PubMed] [Google Scholar]
  • 38.Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. for the STOP-NIDDM Trial Research Group Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Diabetes Care. 2002;359:2072–2077. doi: 10.1016/S0140-6736(02)08905-5. [DOI] [PubMed] [Google Scholar]
  • 39.Marre M., Van Gaal L., Usadel K., Ball M., Whatmough I., Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab. 2002;4:177–186. doi: 10.1046/j.1463-1326.2002.00196.x. [DOI] [PubMed] [Google Scholar]
  • 40.Risso A., Mercuri F., Quagliaro L., Damante G., Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab. 2001;281:E924–E930. doi: 10.1152/ajpendo.2001.281.5.E924. [DOI] [PubMed] [Google Scholar]
  • 41.Jones S., Saunders H.J., Qi W., Pollock C.A. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia. 1999;42:1113–1119. doi: 10.1007/s001250051279. [DOI] [PubMed] [Google Scholar]
  • 42.Li W., Liu X., Yanoff M., Cohen S., Ye X. Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia. 1996;39:537–547. doi: 10.1007/BF00403300. [DOI] [PubMed] [Google Scholar]
  • 43.Muggeo M., Zoppini G., Bonora E., Bonadonna R.C., Moghetti P., Verlato G. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000;23:45–50. doi: 10.2337/diacare.23.1.45. [DOI] [PubMed] [Google Scholar]
  • 44.Brun E., Zoppini G., Zamboni C., Bonora E., Muggeo M. Glucose instability is associated with a high level of circulating p-selectin. Diabetes Care. 2001;24:1685. doi: 10.2337/diacare.24.9.1685. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES